Press release
Cushing's Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration, and Other Developments
Explore Report at: www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis
Cushing’s syndrome is a condition that occurs when a person is exposed to the hormone cortisol at a very high level, for a longer period of time, this is sometimes called as hypercortisolism. It mostly affects obese people at the aged between 20 to 50 years, who have type 2 diabetes and high blood pressure. The symptoms of the Cushing’s syndrome, include, round face, upper body obesity, deposition of fat around neck and relatively lean arms and legs. In some cases, skin of the patients become fragile, heals poorly, bruises easily and purple or pink marks appear on the abdomen, buttocks, thigh and breast. Bones become weakened and spinal and column fracture can occur when person is doing any routine activity like bending, lifting etc. Other symptoms include severe fatigue, increased thirst and urination, irritability, anxiety, depression and weak muscles.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/toc-sample
Corcept Therapeutics is introducing a drug names, CORT125134, GRII receptor antagonist with potential antineoplastic activity which is currently in Phase II stage of clinical development. CORT125134 binds competitively to GRII receptor and prevents the translocation of ligand bind complexes to nucleus for the expression of GR-associated genes. Strongbridge Biopharma Plc plans to introduce a drug by the name COR-003, which is a single enantiomer od ketoconazole with data reflecting the improvement of its therapeutic index as compared to ketoconazole. COR-003 is presently being inspected in Phase III study for the treatment of endogenous Cushing’s syndrome. Millendo Therapeutics, Inc. is in the process of introducing a drug ATR-101 which selectively targets the acyl-CoA: cholesterol acyltransferase 1 enzyme that causes the transformation of free cholesterol to cholesterol ester. Cholesterol ester servez as a reservoir of synthesis of steroids.
Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals
Some of the companies having a pipeline of Cushing’s syndrome therapeutics include Corcept Therapeutics, Millendo Therapeutics, Inc., Strongbridge Biopharma Plc, Novartis AG. Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cushing's Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration, and Other Developments here
News-ID: 539120 • Views: …
More Releases from P&S Market Research - Pharmaceuticals
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of…
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where…
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the…
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.
Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
As per the findings of research, it…
More Releases for Cushing’s
The Cushing’s Disease Treatment Market to grow at an invigorating pace in the …
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease…
Cushing’s syndrome Market Report Analysis With Industry Share
Cushing’s syndrome is the collection of symptoms caused due to the high level of hormones called cortisol. Also known as hypercortisolism, the syndrome is often caused due to side effects of corticosteroid treatment. Corticosteroids are often used for treatment of inflammation and autoimmune conditions. Cushing’s syndrome can be of two types, iatrogenic Cushing’s syndrome and endogenous Cushing’s syndrome. Common symptoms of the syndrome include weight gain, fat tissue deposits around…
Cushing’s Syndrome Therapeutics - Key Players Analysis Novartis, AstraZeneca, …
The study analyzed that the Cushing’s syndrome therapeutics pipeline comprises of approximately 13 drug candidates.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/report-sample
*Specific Targeted Therapy to Provide Various Opportunities
The drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing’s syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.
Some of the players developing drugs…
Cushing’s Syndrome Market Is Projected to Increase Due To Rise in Its Awarenes …
Cushing’s Syndrome is a collection of symptoms and signs, which includes high blood pressure, reddish stretch marks, abdominal obesity, round red face, weak muscles, weak bones, a fat lump between the shoulders and fragile skin that heals slowly due to prolonged exposure to cortisol. Excessive cortisol-like medication such as prednisone or tumor that is produced due to excess cortisol by adrenal glands are the two basic factors that cause Cushing’s…
Cushing’s Disease Treatment Market Forecast over 2017 – 2025
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease…
Cushing’s Disease Treatment Market Forecast over 2017 – 2025
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease…
